These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37660616)

  • 1. A DFT study on the probability of using the heteroatom decorated graphitic carbonitride (g-C
    Hsu CY; Abdul Kareem Al-Hetty HR; Alsailawi HA; Islam S; Shather AH; Mekkey SM; Ahmed AA; Hadrawi SK; Ali Kahi N
    J Mol Graph Model; 2023 Dec; 125():108605. PubMed ID: 37660616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diroximel fumarate to treat multiple sclerosis.
    Wang Y; Bhargava P
    Drugs Today (Barc); 2020 Jul; 56(7):431-437. PubMed ID: 32648853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews.
    Gudesblatt M; Roman C; Singer BA; Schmidt H; Thomas J; Shankar SL; Lyons J; Kapadia S
    Adv Ther; 2022 Jul; 39(7):3199-3213. PubMed ID: 35556227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using the aluminum decorated graphitic-C
    Abbass R; Chlib Alkaaby HH; Kadhim ZJ; Izzat SE; Kadhim AA; Adhab AH; Pakravan P
    J Mol Graph Model; 2022 Dec; 117():108302. PubMed ID: 36049401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diroximel fumarate in the treatment of multiple sclerosis.
    Jonasson E; Sejbaek T
    Neurodegener Dis Manag; 2020 Oct; 10(5):267-276. PubMed ID: 32686599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dimethyl fumarate downregulates the immune response through the HCA
    von Glehn F; Dias-Carneiro RPC; Moraes AS; Farias AS; Silva VAPG; Oliveira FTM; Silva CEBG; de Carvalho F; Rahal E; Baecher-Allan C; Santos LMB
    Mult Scler Relat Disord; 2018 Jul; 23():46-50. PubMed ID: 29763776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of dimethyl fumarate in oxidative stress of multiple sclerosis: A review.
    Suneetha A; Raja Rajeswari K
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Apr; 1019():15-20. PubMed ID: 26899449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diroximel Fumarate as a Novel Oral Immunomodulating Therapy for Relapsing Forms of Multiple Sclerosis: A Review on the Emerging Data.
    Hauer L; Sellner J
    Drug Des Devel Ther; 2022; 16():3915-3927. PubMed ID: 36388086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study.
    Araujo L; Geertsen SS; Amedume A; Higuchi K; van Wingerden J
    Neurol Ther; 2022 Dec; 11(4):1735-1748. PubMed ID: 36152222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
    Wray S; Then Bergh F; Wundes A; Arnold DL; Drulovic J; Jasinska E; Bowen JD; Negroski D; Naismith RT; Hunter SF; Gudesblatt M; Chen H; Lyons J; Shankar SL; Kapadia S; Mendoza JP; Singer BA
    Adv Ther; 2022 Apr; 39(4):1810-1831. PubMed ID: 35211872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of graphitic carbon nitride as a drug delivery system for cisplatin (anticancer drug): A DFT approach.
    Perveen M; Nazir S; Arshad AW; Khan MI; Shamim M; Ayub K; Khan MA; Iqbal J
    Biophys Chem; 2020 Dec; 267():106461. PubMed ID: 32919257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study.
    Palte MJ; Wehr A; Tawa M; Perkin K; Leigh-Pemberton R; Hanna J; Miller C; Penner N
    Adv Ther; 2019 Nov; 36(11):3154-3165. PubMed ID: 31538304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cell-mimicking platelet-based drug delivery system as a potential carrier of dimethyl fumarate for multiple sclerosis.
    Mehdi-Alamdarlou S; Ahmadi F; Azadi A; Shahbazi MA; Heidari R; Ashrafi H
    Int J Pharm; 2022 Sep; 625():122084. PubMed ID: 35944590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dimethyl fumarate: Regulatory effects on the immune system in the treatment of multiple sclerosis.
    Hosseini A; Masjedi A; Baradaran B; Hojjat-Farsangi M; Ghalamfarsa G; Anvari E; Jadidi-Niaragh F
    J Cell Physiol; 2019 Jul; 234(7):9943-9955. PubMed ID: 30536402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers.
    Edwards KR; Kamath A; Button J; Kamath V; Mendoza JP; Zhu B; Plavina T; Woodward C; Penner N
    Mult Scler Relat Disord; 2021 Jun; 51():102861. PubMed ID: 33773271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dimethyl fumarate induced lymphopenia in multiple sclerosis: A review of the literature.
    Dello Russo C; Scott KA; Pirmohamed M
    Pharmacol Ther; 2021 Mar; 219():107710. PubMed ID: 33091427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dimethyl fumarate treatment alters NK cell function in multiple sclerosis.
    Smith MD; Calabresi PA; Bhargava P
    Eur J Immunol; 2018 Feb; 48(2):380-383. PubMed ID: 29108094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
    Naismith RT; Wolinsky JS; Wundes A; LaGanke C; Arnold DL; Obradovic D; Freedman MS; Gudesblatt M; Ziemssen T; Kandinov B; Bidollari I; Lopez-Bresnahan M; Nangia N; Rezendes D; Yang L; Chen H; Liu S; Hanna J; Miller C; Leigh-Pemberton R
    Mult Scler; 2020 Nov; 26(13):1729-1739. PubMed ID: 31680631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azo polymeric micelles designed for colon-targeted dimethyl fumarate delivery for colon cancer therapy.
    Ma ZG; Ma R; Xiao XL; Zhang YH; Zhang XZ; Hu N; Gao JL; Zheng YF; Dong DL; Sun ZJ
    Acta Biomater; 2016 Oct; 44():323-31. PubMed ID: 27544813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate.
    Nicholas JA; Boster AL; Imitola J; O'Connell C; Racke MK
    Drug Des Devel Ther; 2014; 8():897-908. PubMed ID: 25045248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.